Request Legal Help Now - Free
LAWSUITS NEWS & LEGAL INFORMATION

Blood Pressure Medication Micardis May Pose Cancer Risk


Chicago, IL: A new study published in the journal Lancet Oncology, is reporting the potential for increased risk for cancer associated with the use of the blood pressure medication Micardis (telmisartan), an angiotensin receptor blocker (ARB) made by Boehringer Ingelheim.

According to a report on Reuters.com, Dr. Ilke Sipahi and colleagues from Case Western Reserve University in Cleveland and colleagues wrote in the journal Lancet Oncology, "The increased risk of new cancer occurrence is modest but significant."

The analysis done on available data on drugs in that class, showed that patients taking the ARBs were 1.2 percent more likely to be diagnosed with a new cancer over four years, compared with people not on the drugs. However, there were not enough data to show if this is a class effect.

Dr. Steven Nissen, who became famous when he published results on the determental effects of GalsxoSmithKline's diabetes drug Avandia, told Reuters that the findings were "disturbing and provocative, raising crucial drug safety questions for practitioners and the regulatory community."

In 2003, a study done in patients with heart failure who were taking AstraZeneca's ARB Atacand, or candesartan, had a significantly increased risk of fatal cancer, compared with those on placebo.

Legal Help

If you or a loved one has suffered illness or an adverse health event resulting from the use of this product, please click the link below and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.
Last updated on

LEGAL ARTICLES AND INTERVIEWS

Blood Pressure Medication May Pose Cancer Risk
July 19, 2010
Chicago, IL A new study published in the journal Lancet Oncology, is reporting the potential for increased risk for cancer associated with the use of the blood pressure medication Micardis (telmisartan), an angiotensin receptor blocker (ARB) made by Boehringer Ingelheim.
READ MORE

ADD YOUR COMMENT ON THIS ISSUE

Fields marked * are mandatory. Please read our comment guidelines before posting.

*Name:

Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.
*Your Comment:

Are you the defendant or a subject matter expert on this topic with an opposing viewpoint? We'd love to hear your comments here as well, or if you'd like to contact us for an interview please submit your details here.
Request Legal Help Now! - Free